Updated time: 2020-07-24 11:04:05
10T-1090715
2020-07-24
Know-how
Receptor tyrosine-protein kinase (RTK) ERBB3, also named as HER3, belongs to human epidermal growth factor receptor (EGFR) families. HER3 lacks or has little intrinsic tyrosine kinase activity. It often co-expresses and forms herterdimers with other RTKs in cancer cells to activate signaling pathway, especially in PI3k/AKT. Previously studies, elevated HER3 have been observed in a variety of human cancers and found that HER3 expression is related to the drug resistance induced by the use of anti-EGFR or anti-HER2 drugs. Therefore, the development of drugs against HER3 is the important task for pharmaceutical companies. We have screened an anti-HER3 antibody using the phage-displayed human antibody library and used affinity maturation to increase its binding ability. This anti-HER3 antibody can inhibit downstream signal transduction in vitro and inhibit tumor growth in vivo. Compared with AMG888 antibody developed by Amgen, this human antibody revealed strong clinical potential for cancer therapy.
- Blocking HER3 downstream signal transduction.
- Inhibition of tumor growth in vivo.
- Good therapeutic efficacy.
- Treatment for high HER3-expressed cancer patients.
- Combination therapy for cancer patients with EGFR or HER2 drug-resistance.
Han-Chung Wu
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Development of anti-HER3 therapeutic antibodies